- Home
- GLAC vs HOWL Comparison
GLAC vs HOWL Comparison
Compare GLAC & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLAC
- HOWL
- Stock Information
- Founded
- GLAC 2021
- HOWL 2017
- Country
- GLAC China
- HOWL United States
- Employees
- GLAC N/A
- HOWL N/A
- Industry
- GLAC
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- GLAC
- HOWL Health Care
- Exchange
- GLAC Nasdaq
- HOWL Nasdaq
- Market Cap
- GLAC 95.0M
- HOWL 87.4M
- IPO Year
- GLAC 2023
- HOWL 2021
- Fundamental
- Price
- GLAC $10.60
- HOWL $1.79
- Analyst Decision
- GLAC
- HOWL Strong Buy
- Analyst Count
- GLAC 0
- HOWL 2
- Target Price
- GLAC N/A
- HOWL $13.50
- AVG Volume (30 Days)
- GLAC 154.9K
- HOWL 656.6K
- Earning Date
- GLAC 01-01-0001
- HOWL 11-07-2024
- Dividend Yield
- GLAC N/A
- HOWL N/A
- EPS Growth
- GLAC N/A
- HOWL N/A
- EPS
- GLAC N/A
- HOWL N/A
- Revenue
- GLAC N/A
- HOWL $3,386,000.00
- Revenue This Year
- GLAC N/A
- HOWL N/A
- Revenue Next Year
- GLAC N/A
- HOWL $191.98
- P/E Ratio
- GLAC $41.20
- HOWL N/A
- Revenue Growth
- GLAC N/A
- HOWL N/A
- 52 Week Low
- GLAC $10.04
- HOWL $1.58
- 52 Week High
- GLAC $10.84
- HOWL $8.19
- Technical
- Relative Strength Index (RSI)
- GLAC N/A
- HOWL 32.55
- Support Level
- GLAC N/A
- HOWL $1.58
- Resistance Level
- GLAC N/A
- HOWL $2.24
- Average True Range (ATR)
- GLAC 0.00
- HOWL 0.16
- MACD
- GLAC 0.00
- HOWL -0.09
- Stochastic Oscillator
- GLAC 0.00
- HOWL 7.01
About GLAC Global Lights Acquisition Corp
Global Lights Acquisition Corp is a blank check company.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.